Celcuity Inc. (NASDAQ:CELC) Receives Average Rating of “Buy” from Brokerages

Celcuity Inc. (NASDAQ:CELC) has received an average recommendation of “Buy” from the seven brokerages that are presently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $29.17.

CELC has been the topic of a number of recent analyst reports. Stifel Nicolaus increased their price target on shares of Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, October 7th. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Celcuity in a research note on Friday, November 15th. Finally, Needham & Company LLC restated a “buy” rating and set a $23.00 price target on shares of Celcuity in a research report on Friday, November 15th.

Celcuity Stock Performance

Shares of CELC opened at $10.93 on Tuesday. Celcuity has a 52-week low of $10.35 and a 52-week high of $22.19. The stock’s 50-day simple moving average is $12.68 and its 200 day simple moving average is $14.93. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The stock has a market capitalization of $405.83 million, a price-to-earnings ratio of -4.19 and a beta of 0.74.

Hedge Funds Weigh In On Celcuity

Hedge funds and other institutional investors have recently bought and sold shares of the stock. nVerses Capital LLC purchased a new stake in shares of Celcuity during the 3rd quarter valued at $33,000. Prospera Private Wealth LLC bought a new position in Celcuity in the third quarter valued at $35,000. Values First Advisors Inc. purchased a new stake in Celcuity during the third quarter valued at about $86,000. Quest Partners LLC lifted its stake in Celcuity by 31.3% during the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock worth $95,000 after purchasing an additional 1,379 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Celcuity in the 3rd quarter worth about $119,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.